Identification of Key Molecular Players in the Development of Radiation Cystitis Through RNA Sequencing

Document Type

Conference Proceeding

Publication Date

5-2022

Publication Title

Journal of Urology

Abstract

INTRODUCTION AND OBJECTIVE:

Pelvic cancer survivors that were treated with radiation therapy are at risk for developing radiation (hemorrhagic) cystitis (RC) up to 15 years after completion of radiation therapy. Patients with RC suffer from lower urinary tract symptoms, including frequency, nocturia, pelvic pain and incontinence. At an advanced stage, patients can develop hematuria, which can become life-threatening if bleeding cannot be controlled. To date, no safe and reliable therapy exists to treat RC, in part due to the unavailability of bladder biopsies. Taking biopsies of an already fragile bladder is unethical. The objective of this study is to use our established preclinical model to gain insight in the molecular pathways that drive radiation-induced tissue changes in the bladder.

METHODS:

Female C57Bl/6 mice received a single dose of 40 Gy using the SARRP irradiator. Bladder physiology was assessed using void spot assay. Bladders were harvested at different time points (1 week, 4 weeks, 3 months and 6 months) after irradiation, RNA was harvested, and mRNA sequencing was performed at paired-end 150bp on the Illumina NovaSeq6000 with a target of 30 million reads per sample. Following RNA sequencing, thorough bioinformatics analysis was performed. Findings of the RNA sequencing were validated using qPCR analysis.

RESULTS:

At 1-week post-irradiation, altered gene expression was detected in genes involved in DNA damage response, apoptosis, and transcriptional regulation. By 6-months post-irradiation, significant changes in gene expression were observed in vascular health, wound healing, inflammation, and apoptosis. Genes significantly up- or downregulated in these pathways are listed in table 1. Affected pathways include the Wnt signaling, p53, JAK-STAT, and PI3K-Akt pathways. These findings are currently being validated in vitro in human urothelial cells (SV-HUC-1), and in vivo in bladder tissues from our preclinical model.

CONCLUSIONS:

The outcome of these studies will have a tremendous impact on the field. This is the first study to determine the molecular changes in the bladder in response to radiation treatment. We hereby identify the physiological changes that drive the progression of radiation cystitis which will aid in identifying potential therapeutic targets.

Volume

207

Issue

Suppl 5

First Page

e364

Comments

American Urological Association Annual Meeting, May 13-16, New Orleans, LA.

DOI

10.1097/JU.0000000000002559.09

Link to Full Text

Share

COinS